-
Panel explores evolving impact of teplizumab on type 1 diabetes trials, treatment
Teplizumab became the first FDA-approved drug for the delay and prevention of type 1 diabetes, but it also comes with its own challenges. Presenters, including Kevan C. Herold, MD, shared the benefits of teplizumab along with some of the barriers faced for the research community, clinical practice, and patients.
-
DCCT/EDIC proves to be the most impactful research in diabetes history
Before DCCT/EDIC, most individuals with type 1 diabetes died in their late 40s. Four decades later, David M. Nathan, MD, Chair of the DCCT/EDIC Research Group, and other investigators explained how management of the disease has been transformed by the data gleaned from this groundbreaking research and, as a result, lifespans have been extended.
-
Global health experts discuss how inequity fuels international diabetes trends
New statistics indicate that more than 1.31 billion people across the globe could be living with diabetes in the next 30 years. In a special symposium on how inequity contributes to the significant growth in this population, Louise J. Maple-Brown, MBBS, FRACP, PhD, and Sian Graham, BAppSc, discussed how select social determinants of health impact…
-
Debate weighs the efficacy of initial combination therapy for type 2 diabetes
Ralph A. DeFronzo, MD, and David M. Nathan, MD, debated whether combination therapy or sequential therapy is the most effective regimen for treating type 2 diabetes. Dr. DeFronzo advocated for combination therapy for its ability to efficiently correct multiple pathophysiologic defects. Dr. Nathan countered that sequential therapy is a more verifiable and efficient initial approach…